<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356147</url>
  </required_header>
  <id_info>
    <org_study_id>Z4962s</org_study_id>
    <nct_id>NCT01356147</nct_id>
  </id_info>
  <brief_title>Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)</brief_title>
  <acronym>PVAIN</acronym>
  <official_title>Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator
      associated pulmonary infections. Dornase alfa has been effective in the treatment of
      pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria
      causing pulmonary infections in cystic fibrosis patients is similar to those infecting
      preterm infants. The investigators expect that dornase alfa therapy will improve recovery
      from ventilator associated pulmonary infections in preterm infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Reduction in Oxygen Requirement From Baseline</measure>
    <time_frame>First week of treatment or extubation</time_frame>
    <description>Change in required supplemental oxygen from baseline or time to extubation from mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in White Blood Cell Count and Bacterial Load From Tracheal Aspirate</measure>
    <time_frame>During first week of treatment or until extubation whichever is earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days on Ventilator Support</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Pulmonary Infections</condition>
  <arm_group>
    <arm_group_label>Sham placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase alfa</intervention_name>
    <description>2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
    <arm_group_label>Dornase alfa</arm_group_label>
    <other_name>Pulmozyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No therapy will be given to placebo arm</description>
    <arm_group_label>Sham placebo</arm_group_label>
    <other_name>Sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants less than 38 weeks gestation and over 7 days of age

          -  infants with a ventilator associated pulmonary infection, defined as intubated infants
             who have moderate to heavy White Blood Cells (WBCs) on tracheal aspirate, organisms on
             tracheal aspirate gram stain, a positive endotracheal tube culture, a chest x-ray with
             infiltrate, consolidation or atelectasis, an increase in oxygen (FiO2) requirement and
             whom the clinical team decides to treat with systemic antibiotic therapy

        Exclusion Criteria:

          -  Extremely ill infants not expected to survive

          -  Critically ill infants requiring high frequency ventilation

          -  Infants with congenital pneumonia

          -  Infants with congenital malformations of the respiratory system (e.g. Congenital
             diaphragmatic hernia, cystic adenomatoid malformation or tracheo-esophageal fistula)
             Cyanotic congenital heart disease, chromosomal abnormalities and infants with a
             positive newborn screen for cystic fibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown University Hospital NICU</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Melissa Scala</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics, Department of Neonatology</investigator_title>
  </responsible_party>
  <keyword>ventilator associated pulmonary infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Medstar Georgetown University Hospita NICU patients recruited from May 2012 to november 2014</recruitment_details>
      <pre_assignment_details>No enrolled participants were excluded prior to assignment to groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sham Placebo</title>
          <description>No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
Placebo: No therapy will be given to placebo arm</description>
        </group>
        <group group_id="P2">
          <title>Dornase Alfa</title>
          <description>Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Dornase alfa: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham Placebo</title>
          <description>No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
Placebo: No therapy will be given to placebo arm</description>
        </group>
        <group group_id="B2">
          <title>Dornase Alfa</title>
          <description>Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Dornase alfa: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B2" value="33" lower_limit="18" upper_limit="68"/>
                    <measurement group_id="B3" value="31" lower_limit="18" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Reduction in Oxygen Requirement From Baseline</title>
        <description>Change in required supplemental oxygen from baseline or time to extubation from mechanical ventilation</description>
        <time_frame>First week of treatment or extubation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Placebo</title>
            <description>No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
Placebo: No therapy will be given to placebo arm</description>
          </group>
          <group group_id="O2">
            <title>Dornase Alfa</title>
            <description>Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Dornase alfa: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in Oxygen Requirement From Baseline</title>
          <description>Change in required supplemental oxygen from baseline or time to extubation from mechanical ventilation</description>
          <units>percentage FiO2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="-2" upper_limit="23"/>
                    <measurement group_id="O2" value="16.5" lower_limit="-4" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in White Blood Cell Count and Bacterial Load From Tracheal Aspirate</title>
        <time_frame>During first week of treatment or until extubation whichever is earlier</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days on Ventilator Support</title>
        <time_frame>7 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 7 day period of drug or sham treatment then throughout NICU admission</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sham Placebo</title>
          <description>No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
Placebo: No therapy will be given to placebo arm</description>
        </group>
        <group group_id="E2">
          <title>Dornase Alfa</title>
          <description>Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Dornase alfa: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Melissa Scala</name_or_title>
      <organization>Stanford University School of Medicine/Division of Neonatology</organization>
      <phone>650-724-9653</phone>
      <email>mscala@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

